Cipla promoters are likely to sell up to 1.72% stake via a block deal at Rs 1,442 per share, a 6% discount to the current price. This follo...

Cipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamie...

"Post transaction, the entire promoter group, including persons acting in concert, continues to hold 31.67% in the company and remains comm...

Promoters of Cipla, including Person Acting in Concert, sold 2.04 crore shares in a block deal worth around Rs 2,600 crore to create liquid...

Benchmark equities surged for the third consecutive day on Tuesday. PFC, Mankind Pharma, Patanjali Foods, Bharti Airtel, Siemens, and Cipla...

The move, days after the company posted its best annual results, has triggered speculation that more such transactions could be in the offi...

Promoters of drugmaker Cipla are expected to offload 2.53% of their stake in a block deal worth Rs 2637 crore on Wednesday, according to so...

The price range of the block is fixed at Rs 1,289-1,357, taking the total deal value to around Rs 2,637 crore.

While Cipla paid Rs 29 crore for Okasa’s facility in Goa, it bought another plant, owned by Okasa Pharma, located in Satara for Rs 71.93 cr...

The acquisition is part of a two-way transaction under which the Yusuf Khwaja Hamied-run Cipla's wholly-owned arm Medispray Laboratories co...

Ranbaxy, founded by the family of Malvinder and Shivinder Mohan Singh, was at the centre of most of the developments for major part of the ...

The Nifty was at 8,141.50 up 54 points or 0.67 per cent. It touched an intraday record high of 8,146.55 and a low of 8126.15.

At 09:35 a.m.; Cipla was trading 0.6 per cent higher at Rs 560.75. It hit a low of Rs 559 and a high of Rs 565.40 in trade today.

Indian markets are expected to trade in a range. Here is a list of ten stocks which are likely to be in focus today.

Entities controlled by relatives of the promoters hold majority interest in the companies, which own the aforesaid undertakings, it added.

India has rejected a drug patent application of a US multi-national pharma company, paving way for easy access to an important life-saving ...